Location of Repository

CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer

By Pamela S Larson, Benjamin L Schlechter, Chia-Lin King, Qiong Yang, Chelsea N Glass, Charline Mack, Robert Pistey, Antonio de las Morenas and Carol L Rosenberg
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2323395
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles



    1. (2004). Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. Oncology reports
    2. (1996). An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome. Nature genetics
    3. (2006). C: Quantitative analysis of allele imbalance supports atypical ductal hyperplasia lesions as direct breast cancer precursors.
    4. (1996). Characterization of the human p57KIP2 gene: alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis. Human Genetics
    5. (2001). Chemopreventive effects of green tea polyphenols correlate with reversible induction of p57 expression. Anticancer research
    6. (2006). CL: In utero exposure to diethylstilbestrol (DES) does not increase genomic instability in normal or neoplastic breast epithelium. Cancer
    7. (2005). CL: Reliability and reproducibility of gene expression measurements using amplified RNA from laser-microdissected primary breast tissue with oligonucleotide arrays.
    8. (1994). Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell
    9. (1995). Cloning of p57KIP2, a cyclindependent kinase inhibitor with unique domain structure and tissue distribution.
    10. (1998). Cordon-Cardo C: Mutational study of p16CDKN2/MTS1/INK4A and p57KIP2 genes in hetaptocellular carcinoma.
    11. (2000). CW: Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res
    12. (2004). de las Morenas A, Rosenberg CL: Quantitative DNA fingerprinting may distinguish new primary breast cancer from disease recurrence.
    13. (1998). Differential expression of p57KIP2, a maternally imprinted cdk inhibitor, in normal human placenta and gestational trophoblastic disease. Laboratory Investigation
    14. (2006). Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer. International journal of cancer
    15. (2004). E, et al.: Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res
    16. (1996). Elledge SJ, Takahashi T: Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5. Oncogene
    17. (1995). Elledge SJ: p57KIP2, a structurally distinct member of the p21CIP1Cdk inhibitor family, is a candidate tumor suppressor gene. Genes & Development
    18. (1993). Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell
    19. (2006). Epicatechins Purified from Green Tea (Camellia sinensis) Differentially Suppress Growth of Gender-Dependent Human Cancer Cell Lines. Evid Based Complement Alternat Med
    20. (2005). Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin Cancer Res
    21. (2001). Expression of p57/Kip2 protein in hepatocellular carcinoma. Oncology
    22. (2001). Expression of p57/Kip2 protein in pancreatic adenocarcinoma. Pancreas
    23. Expression Omnibus [http://www.ncbi.nlm.nih.gov]
    24. (1996). Feinberg AP: Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc Natl Acad Sci USA
    25. (1996). Feinberg AP: Reduced expression of the cyclin-dependent kinase inhibitor gene p57KIP2 in Wilms' tumor. Cancer Research
    26. (1997). Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res
    27. (2000). Gicquel C: High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors.
    28. (2000). Hamshere MG: A genome-wide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer. Cancer Res
    29. (1994). Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell
    30. (2006). Immunohistochemical analysis of P57(kip2), p53 and hsp60 expressions in premalignant and malignant oral tissues. Oral oncology
    31. (1995). Ingvarsson S: Loss of heterozygosity at chromosome 11 in breast cancer: association of prognostic factors with genetic alterations. British journal of cancer
    32. (2006). Inze D: Cyclin-dependent kinase inhibitors in yeast, animals, and plants: a functional comparison. Critical reviews in biochemistry and molecular biology
    33. (1996). JM: Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anti-cancer drugs
    34. (2005). Multiple mechanisms downregulate CDKN1C in human bladder cancer. International journal of cancer
    35. (1999). Okret S: p57Kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells. Molecular endocrinology
    36. (2005). Orphanides G: Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes. Journal of molecular endocrinology
    37. (1999). P: p57KIP2 expression and loss of heterozygosity during immortal conversion of cultured human mammary epithelial cells. Cancer Res
    38. (2002). Quantitative real-time reverse transcription polymerase chain reaction: normalization to rRNA or single housekeeping genes is inappropriate for human tissue biopsies. Anal Biochem
    39. (1997). Ribonucleic acid expression of the clustered imprinted genes, p57KIP2, insulin-like growth factor II, and H19 in adrenal tumors and cultured adrenal cells.
    40. (2004). RJ: Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells. Anti-cancer drugs
    41. (2006). S: p57(kip2) expression is related to carcinogenesis and tumor progression in laryngeal tissues. Acta oto-laryngologica
    42. (2000). Schulz WA: Decreased expression of p57(KIP2)mRNA in human bladder cancer. British journal of cancer
    43. (2004). SD: Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation.
    44. (2003). The cell cycle-regulated B-Myb transcription factor overcomes cyclin-dependent kinase inhibitory activity of p57(KIP2) by interacting with its cyclinbinding domain. The Journal of biological chemistry
    45. (2005). The role of myoepithelial cells in integration of form and function in the mammary gland. Journal of mammary gland biology and neoplasia
    46. (2000). TL: DNA alterations in tumor scrapes vs. biopsies of squamouscell carcinomas of the head and neck.
    47. (1998). Two distinct tumor suppressor loci within chromosome 11p15 implicated in breast cancer progression and metastatsis. Human Molecular Genetics

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.